Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FARHAN SIDDIQUI

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1447461579
CMS profile
246924
Location
SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,854.28

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,836.00 112
Education $18.28 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FARHAN SIDDIQUI

NPI 1447461579 · CMS profile ID 246924

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

SPARTANBURG, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447461579?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FARHAN SIDDIQUI, NPI 1447461579, CMS profile ID 246924. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447461579?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). FARHAN SIDDIQUI, NPI 1447461579, CMS profile ID 246924. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447461579?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
FARHAN SIDDIQUI, NPI 1447461579, CMS profile ID 246924, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447461579?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $1,854.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Philips Electronics North America Corporation $13.6202/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853246209 CMS
Actelion Pharmaceuticals US, Inc. $16.4102/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788248423 CMS
GENZYME CORPORATION $20.0702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843686743 CMS
AstraZeneca Pharmaceuticals LP $11.8802/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829908941 CMS
GlaxoSmithKline, LLC. $11.7002/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802547750 CMS
Merck Sharp & Dohme Corporation $19.8302/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848710331 CMS
Mallinckrodt Hospital Products Inc. $19.3502/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845379871 CMS
AstraZeneca Pharmaceuticals LP $12.5802/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829848985 CMS
GlaxoSmithKline, LLC. $11.9301/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803043551 CMS
Janssen Pharmaceuticals, Inc $11.1001/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788248409 CMS
AstraZeneca Pharmaceuticals LP $181.7701/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829590673 CMS
Philips Electronics North America Corporation $18.8301/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853246207 CMS
United Therapeutics Corporation $16.4401/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839124679 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,416.98 95
PY2020 $1,033.31 63
PY2021 $1,854.28 113
PY2022 $2,274.28 121
PY2023 $2,775.97 146
PY2024 $5,983.12 142
PY2025 $9,113.57 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $35,300.48 1
PY2025 Principal investigator $3,487,074.32 394
PY2024 Recipient $134,633.42 1
PY2024 Principal investigator $2,116,200.52 534
PY2023 Recipient $2,261.49 1
PY2023 Principal investigator $1,688,933.45 1,034
PY2022 Recipient $54,040.00 3
PY2022 Principal investigator $1,171,894.02 94
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,884.02 3
PY2020 Principal investigator $44,469.20 7
PY2019 Principal investigator $107,645.45 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

395 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $16,802.00 12/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228805770
Principal investigator 1 Currax Pharmaceuticals LLC $1,642.89 12/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718378
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279455
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279457
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279459
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279461
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279463
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279465
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279467
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279469
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279471
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279473
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279475
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279477
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279479
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279481
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280415
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280419
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280421
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280423
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280425
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280427
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280429
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280431
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280433
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280435
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280437
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280439
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280441
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280443
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280445
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280447
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280651
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280653
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280655
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280657
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280659
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280661
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280663
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280771
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280773
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280775
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280777
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280779
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280781
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280783
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280785
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280787
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280803
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280805
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280807
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280809
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280811
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280813
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280815
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280817
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280819
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280821
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281027
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281029
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281031
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281033
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281035
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281037
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281039
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281041
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281043
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281045
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281047
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281049
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281051
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281053
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281055
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281057
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281059
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281061
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281063
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281065
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281067
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281069
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281071
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281073
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281075
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281077
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281079
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281081
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281083
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281085
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281087
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281089
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281091
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281093
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281095
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281097
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281099
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281101
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281103
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281105
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281107
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281111
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281113
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281115
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281117
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281119
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281121
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281123
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281125
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281127
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281129
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281131
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281133
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281135
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281137
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281139
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281141
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281143
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281145
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281147
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281149
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281151
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281153
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281155
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281157
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281159
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281161
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281163
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281165
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281167
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281169
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281171
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281173
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281175
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281177
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281179
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281183
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281185
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281187
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281189
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281191
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281193
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281195
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281197
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281199
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281201
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281203
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281205
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281207
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281209
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281211
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281213
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281215
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281217
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281219
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281221
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281223
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281227
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281229
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281231
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185281435
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273918
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273920
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273922
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273924
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273926
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273928
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273930
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273932
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273934
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273936
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273938
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273940
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273942
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273944
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273946
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273948
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273950
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273952
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273970
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273972
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273974
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273976
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273978
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273980
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273982
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273984
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273986
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273988
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273990
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273992
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273995
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273998
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274000
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274002
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274004
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274006
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274008
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274010
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274012
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274014
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274016
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274018
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274020
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274022
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274024
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274026
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274028
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274030
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274032
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274034
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274036
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274038
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274040
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274276
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274278
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274280
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274282
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274284
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274286
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274308
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274310
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274312
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274314
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274316
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274318
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274320
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274322
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274326
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274328
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274330
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274332
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274334
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274336
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274338
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274340
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274342
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274344
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274346
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274348
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274350
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274352
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274354
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274356
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274358
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274360
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274362
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274364
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274366
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274368
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274370
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274372
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274374
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274376
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275600
Principal investigator 1 Seqirus USA Inc $1,019.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275604
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275606
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275608
Principal investigator 1 Verona Pharma, Inc. $30,640.24 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891935
Principal investigator 1 Verona Pharma, Inc. $24,128.69 12/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891933
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $1,396.75 12/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH SPARTANBURG
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy? No dispute reported 06/30/2026 1214124830
Principal investigator 1 ModernaTX, Inc. $11,432.30 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968901
Principal investigator 1 ModernaTX, Inc. $4,175.25 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968909
Principal investigator 1 ModernaTX, Inc. $25,811.50 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968939
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810506
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810511
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810517
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810585
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810592
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810599
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810676
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810681
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228810687
Principal investigator 1 PFIZER INC. $426.60 11/25/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228811165
Principal investigator 1 ModernaTX, Inc. $204.90 11/21/2025 Non-covered Recipient Entity
Velocity Clinical Research, Spartanburg
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968925
Principal investigator 1 PFIZER INC. $265.20 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228805814
Principal investigator 1 PFIZER INC. $180.80 11/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Spartanburg
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228805821
Principal investigator 1 Currax Pharmaceuticals LLC $14,130.40 11/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718222
Principal investigator 1 Seqirus USA Inc $4,530.44 11/12/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809785
Principal investigator 1 Seqirus USA Inc $1,291.95 11/12/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809788
Principal investigator 1 Verona Pharma, Inc. $100,404.11 11/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891931
Principal investigator 1 GlaxoSmithKline, LLC. $15,500.00 11/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192144028
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 11/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192182978
Principal investigator 1 Verona Pharma, Inc. $13,199.88 11/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232891929
Principal investigator 1 Seqirus USA Inc $4,103.04 10/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810017
Principal investigator 1 Seqirus USA Inc $1,127.52 10/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250810021
Principal investigator 1 ModernaTX, Inc. $598.68 10/29/2025 Non-covered Recipient Entity
Velocity Clinical Research, Spartanburg
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968891
Principal investigator 1 ModernaTX, Inc. $7,793.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968865
Principal investigator 1 ModernaTX, Inc. $11,599.50 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968935
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 10/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192182294
Principal investigator 1 Currax Pharmaceuticals LLC $13,555.81 10/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718084
Principal investigator 1 GlaxoSmithKline, LLC. $13,467.29 10/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A PROSPECTIVE COHORT STUDY OF PATIENTS WITH REFRACTORY OR UNEXPLAINED No dispute reported 06/30/2026 1192182299
Principal investigator 1 ModernaTX, Inc. $11,077.00 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968861
Principal investigator 1 ModernaTX, Inc. $13,639.15 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968923
Principal investigator 1 Verona Pharma, Inc. $13,500.00 09/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892106
Principal investigator 1 Verona Pharma, Inc. $2,400.00 09/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1232892108
Principal investigator 1 Verona Pharma, Inc. $16,000.00 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Verona No dispute reported 06/30/2026 1232892112
Principal investigator 1 Verona Pharma, Inc. $2,500.00 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Verona No dispute reported 06/30/2026 1232892114
Principal investigator 1 GlaxoSmithKline, LLC. $728.00 09/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182988
Principal investigator 1 Seqirus USA Inc $110.98 09/02/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276814
Principal investigator 1 Seqirus USA Inc $111.30 09/02/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276822
Principal investigator 1 Seqirus USA Inc $1,893.60 09/02/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276870
Recipient Nielsen BioSciences, Inc. $35,300.48 08/31/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1214252109
Principal investigator 1 ModernaTX, Inc. $686.85 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968871
Principal investigator 1 ModernaTX, Inc. $15,884.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968883
Principal investigator 1 ModernaTX, Inc. $12,804.10 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968941
Principal investigator 1 ModernaTX, Inc. $12,686.30 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968955
Principal investigator 1 Seqirus USA Inc $2,000.00 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276874
Principal investigator 1 Seqirus USA Inc $14,500.00 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276878
Principal investigator 1 Seqirus USA Inc $27,126.40 08/28/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276886
Principal investigator 1 GlaxoSmithKline, LLC. $7,017.80 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
REAL-WORLD EFFECTIVENESS OF MEPOLIZUMAB IN TREATING CHRONIC OBSTRUCTIV No dispute reported 06/30/2026 1192182983
Principal investigator 1 GlaxoSmithKline, LLC. $2,095.00 08/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144044
Principal investigator 1 AstraZeneca UK Limited $114,425.30 07/30/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Double Blind,Multicentre,Randomized,Three Period,Three Treatment,CrossOver Study to Evaluate the Effect of BGF MDI,BFF MDI,and Placebo MDI on Exercise Parameters in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1185550920
Principal investigator 1 ModernaTX, Inc. $1,985.50 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968853
Principal investigator 1 ModernaTX, Inc. $2,821.50 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968943
Principal investigator 1 GlaxoSmithKline, LLC. $1,214.00 07/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182315
Principal investigator 1 ModernaTX, Inc. $4,453.60 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968859
Principal investigator 1 ModernaTX, Inc. $29,782.50 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968899
Principal investigator 1 ModernaTX, Inc. $8,652.60 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968907
Principal investigator 1 Currax Pharmaceuticals LLC $3,480.78 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717936
Principal investigator 1 Currax Pharmaceuticals LLC $182.00 06/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242718012
Principal investigator 1 Currax Pharmaceuticals LLC $1,020.50 06/19/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717679
Principal investigator 1 ModernaTX, Inc. $686.85 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968855
Principal investigator 1 ModernaTX, Inc. $46,659.25 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968857
Principal investigator 1 ModernaTX, Inc. $12,226.50 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968893
Principal investigator 1 ModernaTX, Inc. $13,082.45 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968953
Principal investigator 1 GlaxoSmithKline, LLC. $4,764.00 06/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144036
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185550918
Principal investigator 1 ModernaTX, Inc. $26,164.90 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968897
Principal investigator 1 ModernaTX, Inc. $45,666.50 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968919
Principal investigator 1 ModernaTX, Inc. $12,372.80 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968933
Principal investigator 1 ModernaTX, Inc. $686.85 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968937
Principal investigator 1 AstraZeneca Pharmaceuticals LP $300.00 06/06/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185550910
Principal investigator 1 Genentech, Inc. $6,498.00 06/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211682210
Principal investigator 1 Currax Pharmaceuticals LLC $12,815.42 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717859
Principal investigator 1 Verona Pharma, Inc. $2,800.00 05/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892072
Principal investigator 1 ModernaTX, Inc. $1,373.70 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968911
Principal investigator 1 ModernaTX, Inc. $41,195.80 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968913
Principal investigator 1 ModernaTX, Inc. $11,745.80 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968917
Principal investigator 1 Currax Pharmaceuticals LLC $10,854.73 04/24/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717727
Principal investigator 1 ModernaTX, Inc. $2,496.37 04/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252968877
Principal investigator 1 GlaxoSmithKline, LLC. $1,034.00 04/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144053
Principal investigator 1 GlaxoSmithKline, LLC. $712.00 04/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182307
Principal investigator 1 GlaxoSmithKline, LLC. $1,214.00 04/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182311
Principal investigator 1 GlaxoSmithKline, LLC. $947.00 04/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182324
Principal investigator 1 ModernaTX, Inc. $11,327.80 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968867
Principal investigator 1 ModernaTX, Inc. $35,072.10 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968881
Principal investigator 1 ModernaTX, Inc. $15,884.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968915
Principal investigator 1 ModernaTX, Inc. $41.80 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968945
Principal investigator 1 ModernaTX, Inc. $1,373.70 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968957
Principal investigator 1 Verona Pharma, Inc. $5,000.00 03/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892064
Principal investigator 1 Currax Pharmaceuticals LLC $35,920.17 03/05/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717543
Principal investigator 1 ModernaTX, Inc. $13,187.90 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968885
Principal investigator 1 ModernaTX, Inc. $14,330.75 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968895
Principal investigator 1 ModernaTX, Inc. $31,453.55 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968921
Principal investigator 1 ModernaTX, Inc. $3,434.25 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968927
Principal investigator 1 ModernaTX, Inc. $4,263.60 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968947
Principal investigator 1 ModernaTX, Inc. $27,797.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968951
Principal investigator 1 AstraZeneca Pharmaceuticals LP $64,690.40 02/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185550908
Principal investigator 1 ModernaTX, Inc. $1,200.00 02/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252968879
Principal investigator 1 ModernaTX, Inc. $550.00 02/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252968905
Principal investigator 1 PFIZER INC. $20,480.85 02/22/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228835935
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $102,059.90 02/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH SPARTANBURG
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123670
Principal investigator 1 ModernaTX, Inc. $140,441.35 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968887
Principal investigator 1 Verona Pharma, Inc. $12,059.05 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892038
Principal investigator 1 AstraZeneca UK Limited $64,893.00 02/14/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185550914
Principal investigator 1 PFIZER INC. $18,000.00 02/14/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228835941
Principal investigator 1 Currax Pharmaceuticals LLC $7,257.25 02/13/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717175
Principal investigator 1 Eli Lilly and Company $123,848.00 02/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893544
Principal investigator 1 Eli Lilly and Company $4,248.46 02/10/2025 Non-covered Recipient Entity
KEYSTONE RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885944
Principal investigator 1 GlaxoSmithKline, LLC. $637.00 02/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144032
Principal investigator 1 GlaxoSmithKline, LLC. $1,511.00 02/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144040
Principal investigator 1 GlaxoSmithKline, LLC. $2,035.00 02/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192144049
Principal investigator 1 GlaxoSmithKline, LLC. $637.00 02/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182303
Principal investigator 1 GlaxoSmithKline, LLC. $891.00 02/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182974
Principal investigator 1 ModernaTX, Inc. $4,200.00 02/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968851
Principal investigator 1 ModernaTX, Inc. $1,200.00 02/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968875
Principal investigator 1 Currax Pharmaceuticals LLC $1,100.00 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717293
Principal investigator 1 Currax Pharmaceuticals LLC $5,245.56 01/30/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242717363
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,439.60 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185550912
Principal investigator 1 ModernaTX, Inc. $7,189.10 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252968873
Principal investigator 1 ModernaTX, Inc. $59,565.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968863
Principal investigator 1 ModernaTX, Inc. $9,237.80 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968869
Principal investigator 1 ModernaTX, Inc. $83,118.35 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968889
Principal investigator 1 ModernaTX, Inc. $10,366.40 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968903
Principal investigator 1 ModernaTX, Inc. $24,773.15 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968931
Principal investigator 1 ModernaTX, Inc. $2,747.40 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968949
Principal investigator 1 ModernaTX, Inc. $68.30 01/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH SPARTANBURG
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252968929
Principal investigator 1 GlaxoSmithKline, LLC. $2,928.00 01/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192182320
Principal investigator 1 Verona Pharma, Inc. $82,746.75 01/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892034
Principal investigator 1 Verona Pharma, Inc. $43,372.75 01/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD No dispute reported 06/30/2026 1232892036
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278943
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278945
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278947
Principal investigator 1 Seqirus USA Inc $1,088.00 01/06/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185278949
Principal investigator 1 AstraZeneca Pharmaceuticals LP $230,944.40 01/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185550916
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $662,564.06 01/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH SPARTANBURG
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123410